NASDAQ:ENLV Enlivex Therapeutics Q1 2024 Earnings Report $1.15 -0.03 (-2.13%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$1.13 -0.02 (-1.74%) As of 10/10/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Enlivex Therapeutics EPS ResultsActual EPS-$0.22Consensus EPS -$0.25Beat/MissBeat by +$0.03One Year Ago EPSN/AEnlivex Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEnlivex Therapeutics Announcement DetailsQuarterQ1 2024Date6/14/2024TimeN/AConference Call DateThursday, June 13, 2024Conference Call Time6:00PM ETUpcoming EarningsEnlivex Therapeutics' Q1 2025 earnings is scheduled for Friday, December 5, 2025Conference Call ResourcesInterim ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsInterim report Enlivex Therapeutics Earnings HeadlinesEnlivex Therapeutics to Join Live Investor Webinar on Knee Osteoarthritis Treatment AdvancesSeptember 29, 2025 | quiverquant.comQD. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis ProgramSeptember 29, 2025 | globenewswire.comCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holding investments longer to using tax-advantaged accounts and strategic loss offsetting, there are ways to reduce your exposure. SmartAsset outlines three capital gains tax strategies for seniors and offers a free tool to connect you with vetted fiduciary financial advisors who can help tailor these tactics to your situation.October 11 at 2:00 AM | SmartAsset (Ad)D. Boral Capital Maintains Enlivex Therapeutics (ENLV) Buy RecommendationSeptember 26, 2025 | msn.comWill Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?September 14, 2025 | finance.yahoo.comWill Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?September 14, 2025 | finance.yahoo.comSee More Enlivex Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Enlivex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enlivex Therapeutics and other key companies, straight to your email. Email Address About Enlivex TherapeuticsEnlivex Therapeutics (NASDAQ:ENLV) is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings. The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system. Allocetra is currently being evaluated in clinical trials for indications such as sepsis, acute respiratory distress syndrome (ARDS), and cytokine storm associated with COVID-19. Enlivex’s pipeline also explores the potential of macrophage-based treatments to reduce complications in stem cell transplantation and support cancer therapies by mitigating treatment-related hyperinflammation. Enlivex collaborates with academic medical centers and contract research organizations across North America and Europe to advance its clinical programs. The management team brings expertise in immunology, cell therapy manufacturing, and regulatory affairs, positioning the company to scale production and pursue global regulatory approvals. Enlivex continues to build strategic partnerships aimed at broadening access to its cell-based immunotherapies for patients facing severe inflammatory disorders.View Enlivex Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings Fastenal (10/13/2025)America Movil (10/14/2025)Wells Fargo & Company (10/14/2025)Citigroup (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)The Goldman Sachs Group (10/14/2025)BlackRock (10/14/2025)ASML (10/15/2025)Kinder Morgan (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
